OVID — Ovid Therapeutics Share News
0.000.00%
Last trade - 00:00- $462.86m
- $345.64m
- $7.25m
Brief: Marinus Pharmaceuticals Says On August 17, The PTAB Granted Co's Petition Seeking Post-Grant Review Of Ovid Therapeutics'
Ovid Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Ovid Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Ovid Therapeutics Reports Second Quarter 2023 Financial Results
Brief: Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Brief: Ovid Therapeutics Added To Russell 3000® Index
Ovid Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Ovid Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Ovid Therapeutics Reports First Quarter 2023 Financial Results And Corporate Updates
Brief: Ovid Therapeutics Announces Collaboration With Graviton Bioscience, Proven Developers Of Selective Rock2 Inhibitors
Pfizer, hundreds of US drugmakers call for reversal of Texas abortion pill ruling (updated)
Ovid Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ovid Therapeutics Reports Business Update, Fourth Quarter And Full Year 2022 Financial Results
Brief: Ovid Therapeutics Inc Confirms It Does Not Hold Any Deposits Or Securities At Silicon Valley Bank
Ovid Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Ovid Therapeutics Doses Healthy Volunteers With OV329 In Phase 1 Trial
Ovid Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Ovid Therapeutics Reports Q3 Financial Results, Corporate Highlights
Ovid Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview